South Africa is about to take a significant leap forward in HIV prevention with the upcoming local production of antiHIV injections. The South African branch of Cipla, an Indian pharmaceutical company, is set to manufacture a generic version of the longacting cabotegravir (CABLA) HIV prevention injection at its plants in Benoni and Durban. This development marks a significant step in providing accessible and effective HIV prevention in South Africa. It has the potential to make a substantial impact on HIV infection rates and the overall health of the population.
